BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Dr. Reddy’s Laboratories Ltd. announced settlement of Revlimid (lenalidomide) patent litigation in U.S. with innovator Celgene (subsidiary of Bristol Myers Squibb).
As per the settlement, Celgene would provide Dr. Reddys with a license to sell generic Revlimid from a date after March 2022 (post Natco Pharma Ltd.’s launch) with a constraint of volume market share.
This license agreement would continue until January 2026, post which the company would be able to sell without any constraint.
This development provides certainty to launch and a material earnings accretion over FY23-FY26.
We estimate Dr. Reddys to generate cumulative sales and profit after tax of 2.5 billion U.S dollar and 1.6 billion U.S dollar respectively over this shared exclusivity period.
We this opportunity at Rs 514 per share for Dr. Reddys considering annual market size of 8 billion U.S dollar and gradual market share increase to 18% in FY26.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR